Alphabet’s Verily to sell Granular insurance business to Elevance Health

Alphabet’s Verily to sell Granular insurance business to Elevance Health


Verily headquarters in San Bruno, California.

Courtesy: Verily

Verily is selling its stop-loss insurance subsidiary, Granular Insurance Company, to the insurance provider Elevance Health, the Alphabet health tech company confirmed to CNBC on Thursday.

Verily is one of Google’s sister companies and operates within Alphabet’s “Other Bets” category. The Granular sale is the latest in a series of sweeping changes at the precision health company, which has slashed its workforce, restructured its business and overhauled its executive leadership in recent years.

The terms of the deal were not disclosed. 

Verily launched Granular, initially called Coefficient Insurance Company, in 2020 with financial backing from the commercial insurance unit of the Swiss Re Group. The business offered self-funded employers and captives medical stop-loss, fronting reinsurance and fronting solutions that used “proprietary technology,” Verily said.

Alphabet’s health company has raised more than $1 billion, and it has attracted big-name talent. Apple’s former head of health strategic initiatives, Myoung Cha, joined Verily as chief product officer last year, and Andrew Trister, Verily’s chief medical and scientific officer, was a founding member of Apple’s health team. Amy Abernethy, who served as principal deputy commissioner at the U.S. Food and Drug administration, joined the company in 2021 before departing in late 2023. 

But Verily has struggled to find and stick to a winning niche in health care. 

The company started as a moonshot in 2015 within Alphabet’s innovation lab X, formerly Google X, where it developed hardware like continuous glucose monitors. Verily pivoted to pandemic response when Covid-19 broke out in 2020, and it switched directions again to focus on precision medicine in 2022.

Verily introduced a new artificial intelligence-powered chronic care solution in June called Lightpath. The first offering is metabolic health focused, and it will support patients taking the blockbuster weight loss medications called GLP-1s, using continuous glucose monitors or other interventions, according to a release.

And now, the company is getting out of the insurance business.

Elevance Health did not immediately respond to CNBC’s request for comment. The deal was first reported by Business Insider.

Watch: Alphabet shares sink after mixed Q4 results

Alphabet shares sink after mixed Q4 results



Source

Supreme Court endorses Obamacare panel that requires free preventive care
Health

Supreme Court endorses Obamacare panel that requires free preventive care

Demonstrators in support of U.S. President Barack Obama’s health-care law, the Affordable Care Act (ACA), hold up ‘ACA is Here to Stay’ signs after the U.S. Supreme Court ruled 6-3 to save Obamacare tax subsidies outside the Supreme Court in Washington, D.C. June 25, 2015. Andrew Harrer | Bloomberg | Getty Images WASHINGTON — The […]

Read More
Supreme Court rules for South Carolina over bid to defund Planned Parenthood
Health

Supreme Court rules for South Carolina over bid to defund Planned Parenthood

Planned Parenthood signage is displayed outside of a health care clinic in Los Angeles, California on May 16, 2023.  Patrick T. Fallon | AFP | Getty Images WASHINGTON — The Supreme Court on Thursday ruled for South Carolina over its effort to defund Planned Parenthood, concluding that individual Medicaid patients cannot sue to enforce their […]

Read More
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Health

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Competition in […]

Read More